{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-41772149-semaglutide:v1","objectPathId":"pubmed-pmid-41772149-semaglutide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-41772149-semaglutide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41772149-semaglutide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41772149-semaglutide-v1.md"},"story":{"slug":"pubmed-pmid-41772149-semaglutide","version":1,"domain":"Literature metadata","dateInSource":"2026-07-10","sourceCheckedAt":"2026-08-10","publishedAt":"2026-08-13","peptideSlugs":["semaglutide"],"peptides":[{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"}]},"claims":[{"id":"headline","text":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.","sourceIds":["pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd"]},{"id":"summary","text":"PubMed lists PMID 41772149 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd"]},{"id":"paragraph-1","text":"PubMed lists PMID 41772149 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd"]}],"sources":[{"id":"pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd","name":"PubMed","sourceClass":"A","title":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. · retained source version 1:2026-07-10:current:fa03fbbeb8bd051c19fee899331a07ff6c40320343154ba67107bf893a9edb4a","url":"https://pubmed.ncbi.nlm.nih.gov/41772149/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7dee7936f490a47642c299038e70a31d9880e5005f603b95a6e2f603664d446c","tierARecordSha256":"404fbfd05bd31b51987d46839fd09d2b43bcbdfbf7c8b353054be44325fb2c42"},"integrity":{"algorithm":"sha256","contentSha256":"b93e3b1ce25e204d4f4d00de23f051fc1bd7fb45404ae1a390e2ee764226553e"}}